Home / Tag Archives: Secukinumab

News: Secukinumab


Secukinumab treatment of moderate to severe plaque psoriasis in routine clinical care

Secukinumab

Abstract Background Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, has demonstrated efficacy and safety in patients with moderate to severe psoriasis. However, as per study protocols, transition periods from prior psoriasis treatments of a defined minimal length were required and use of concomitant psoriasis medication was prohibited. There is therefore …

Read More »

Secukinumab safe and effective through 5 years in psoriasis

secukinumab

The improved skin clearance and favorable safety profile achieved with the interleukin-17A (IL-17A) inhibitor secukinumab is maintained through at least five years of treatment, new data suggest. The findings, presented here at the 26th European Academy of Dermatology and Venereology (EADV) Congress in Geneva, are based on the patients originally …

Read More »

Secukinumab effective for moderate to severe scalp psoriasis

secukinumab

FROM THE JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY Secukinumab is a safe and effective treatment option for patients with moderate to severe scalp psoriasis, according to Dr. Jerry Bagel of the Psoriasis Treatment Center of Central New Jersey, and his associates.  After 12 weeks of treatment with 300 mg …

Read More »